Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search

		Submit


Tuberculosis (TB)








Reported Tuberculosis in the United States, 2020						Print
																Related Pages
					Return to Main Menu
Table 23. Tuberculosis Risk Factors,1 by Origin and Race/Ethnicity: United States, 2020
See Surveillance Slide #58.
Table 23. Tuberculosis Risk Factors, by Origin and Race/Ethnicity: United States, 2019
Total Eligible Cases2
Contact3
Non-HIV Immuno-Suppression4
Diabetes Mellitus
Post-Organ Transplantation
TNF-α Inhibitors
Other5
None
UnknownNo.
(%)
No.
(%)
No.
(%)
No.
(%)
No.
(%)
No.
(%)
No.
(%)
No.
(%)**United States**
**7,145**
**532**
**(7.4)**
**660**
**(9.2)**
**1,610**
**(22.5)**
**65**
**(0.9)**
**49**
**(0.7)**
**1,730**
**(24.2)**
**3,169**
**(44.4)**
**322**
**(4.5)****U.S.-born**
**U.S.-born Total**
**2,018**
**319**
**(15.8)**
**198**
**(9.8)**
**288**
**(14.3)**
**15**
**(0.7)**
**17**
**(0.8)**
**536**
**(26.6)**
**815**
**(40.4)**
**103**
**(5.1)**American Indian/Alaska Native
79
28
(35.4)
7
(8.9)
14
(17.7)
0
(0.0)
0
(0.0)
19
(24.1)
22
(27.8)
3
(3.8)Asian
97
21
(21.6)
5
(5.2)
6
(6.2)
0
(0.0)
0
(0.0)
25
(25.8)
47
(48.5)
4
(4.1)Black/African American
730
106
(14.5)
59
(8.1)
100
(13.7)
5
(0.7)
3
(0.4)
210
(28.8)
308
(42.2)
34
(4.7)Hispanic/Latino6
479
91
(19.0)
37
(7.7)
78
(16.3)
2
(0.4)
5
(1.0)
105
(21.9)
195
(40.7)
24
(5.0)Multiple races7
16
4
(25.0)
2
(12.5)
3
(18.8)
0
(0.0)
0
(0.0)
4
(25.0)
9
(56.3)
0
(0.0)Native Hawaiian/Other Pacific Islander
44
21
(47.7)
3
(6.8)
8
(18.2)
0
(0.0)
1
(2.3)
4
(9.1)
10
(22.7)
3
(6.8)White
569
47
(8.3)
84
(14.8)
79
(13.9)
8
(1.4)
7
(1.2)
169
(29.7)
224
(39.4)
34
(6.0)Unknown
4
1
(25.0)
1
(25.0)
0
(0.0)
0
(0.0)
1
(25.0)
0
(0.0)
0
(0.0)
1
(25.0)**Non-U.S.–born**
**Non-U.S.–born Total**
**5,127**
**213**
**(4.2)**
**462**
**(9.0)**
**1,322**
**(25.8)**
**50**
**(1.0)**
**32**
**(0.6)**
**1,194**
**(23.3)**
**2,354**
**(45.9)**
**219**
**(4.3)**American Indian/Alaska Native
0
0
...
0
...
0
...
0
...
0
...
0
...
0
...
0
...Asian
2,466
75
(3.0)
250
(10.1)
683
(27.7)
33
(1.3)
19
(0.8)
613
(24.9)
1,080
(43.8)
100
(4.1)Black/African American
671
30
(4.5)
37
(5.5)
85
(12.7)
1
(0.1)
2
(0.3)
150
(22.4)
387
(57.7)
26
(3.9)Hispanic/Latino6
1,643
93
(5.7)
139
(8.5)
480
(29.2)
13
(0.8)
9
(0.5)
341
(20.8)
737
(44.9)
61
(3.7)Multiple races7
34
2
(5.9)
4
(11.8)
10
(29.4)
1
(2.9)
0
(0.0)
10
(29.4)
13
(38.2)
3
(8.8)Native Hawaiian/Other Pacific Islander
71
10
(14.1)
5
(7.0)
33
(46.5)
0
(0.0)
0
(0.0)
17
(23.9)
21
(29.6)
5
(7.0)White
216
2
(0.9)
23
(10.6)
25
(11.6)
2
(0.9)
2
(0.9)
56
(25.9)
107
(49.5)
21
(9.7)Unknown
26
1
(3.8)
4
(15.4)
6
(23.1)
0
(0.0)
0
(0.0)
7
(26.9)
9
(34.6)
3
(11.5)1Includes the number of risk factors reported (which may be more than one per case) and the number of cases with no information on additional risk factors. The sum of risk factors is greater than the total number of cases because more than one risk factor may be selected per case.2Excludes TB risk factor information for 29 cases with unknown origin.3Includes risk factor responses of MDR patient contact, missed contact, and infectious TB patient contact.4Includes risk factor responses of end-stage renal disease and non-HIV immunosuppression.5Includes risk factor responses of incomplete LTBI therapy and Other.6Persons of Hispanic/Latino origin may be of any or multiple race.7Indicated two or more races reported for a person, and does not include persons of Hispanic/Latino origin.
**Note:** Case counts for race categories (American Indian/Alaska Native, Asian, Black/African American, Native Hawaiian/Other Pacific Islander, and White) are mutually exclusive and do not include persons of Hispanic ethnicity or multiple race.
Ellipses (...) indicate that the percentage cannot be calculated, and the denominator is 0.Table Printing Tips
							
					
							Last Reviewed:  October 26, 2020						Source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention
					Facebook
        Twitter
        LinkedIn
        Syndicate homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue